Gossamer Bio (Gossamer Bio) Interest Expense : $-13.51 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Gossamer Bio Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Gossamer Bio's interest expense for the three months ended in Dec. 2023 was $ -3.24 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-13.51 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Gossamer Bio's Operating Income for the three months ended in Dec. 2023 was $ -39.03 Mil. Gossamer Bio's Interest Expense for the three months ended in Dec. 2023 was $ -3.24 Mil. Gossamer Bio did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gossamer Bio Interest Expense Historical Data

The historical data trend for Gossamer Bio's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Interest Expense Chart

Gossamer Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-1.94

-12.67

-19.44

-13.88

-13.51

Gossamer Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-3.46	-3.50	-3.43	-3.34	-3.24

Gossamer Bio Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.51 Mil.

Gossamer Bio (NAS:GOSS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gossamer Bio's Interest Expense for the three months ended in Dec. 2023 was $-3.24 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-39.03 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $197.55 Mil.

Gossamer Bio's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Gossamer Bio did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Gossamer Bio (Gossamer Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (NAS:GOSS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

4GB:Germany

Address

3013 Science Park Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.gossamerbio.com

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Executives

Sandra Milligan	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Bryan Giraudo	officer: Chief Financial Officer	7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Richard Aranda	officer: Chief Medical Officer	3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Faheem Hasnain	director, officer: Executive Chairman	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waage Christian	officer: EVP & General Counsel	RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Caryn Peterson	officer: EVP, Regulatory Affairs	3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Laura Carter	officer: Chief Scientific Officer	3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Luisa Salter-cid	officer: Chief Scientific Officer	C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121
Jakob Dupont	officer: Chief Medical Officer	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Sheila Gujrathi	director, officer: President & CEO	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp Manager, Ltd.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Otello Stampacchia	director, 10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Russell J. Cox	director	C/O JAZZ PHARMACEUTICALS, PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2